Termination Archives - Spark Newswire

1 minute read

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept’s ‘OCA In NASH May Never Occur

May 22, 4:20 PM

On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH)

CBAY

1 minute read

Piper Sandler Suspends Coupa Software Rating And Price Target

By Benzinga Newsdesk

December 13, 8:54 AM

Piper Sandler analyst Brent Bracelin suspends Coupa Software (NASDAQ:COUP) rating and price target.

COUP

2 minute read

After A 97% Fall, Could Carvana Shares Be Heading To 10 Cents? Here’s Why One Analyst Thinks So

By Chris Katje

November 7, 7:54 PM

Online used car company Carvana Co (NYSE: CVNA) has had a rough year in 2022 with shares down 97%. One analyst was throwing in the towel and thought shares could actually fall further.

CVNA

2 minute read

Why This Analyst Thinks ‘Fed Pivot Trade’ Could Go Into Overdrive On Friday — It’s Linked To Sept Jobs Data

By Shanthi Rexaline

October 7, 2:29 AM

This week, the market has flattered only to deceive. After starting with two strong sessions, the momentum faded midweek as the data-dependent Federal Reserve kept traders on tenterhooks. Come Friday, traders would get to digest key economic data that could have a say on the central bank’s upcoming rate decisions for the year.

SPY

1 minute read

Apple Hypes ‘Far Out’ Event For September, But This Analyst Says There’s A ‘Bigger Story’

By Shanthi Rexaline

August 25, 9:26 AM

Apple Inc. (NASDAQ: AAPL) recently sent out invitations to its “Far Out” event slated to be held at the Steve Jobs Theater in Cupertino, California on Sept. 7.

AAPL